Hanew K, Utsumi A, Tanaka A, Ikeda H, Yokogoshi Y
Hanew Endocrine Clinic, Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
J Clin Endocrinol Metab. 1998 Oct;83(10):3578-83. doi: 10.1210/jcem.83.10.5171.
The GH secretory mechanism of GH-releasing hexapeptide (GHRP-6), GHRH, and TRH were studied in vivo and in vitro in seven patients with acromegaly. In an in vivo study, these patients showed clear GH responses to single administration of GHRP (four of four patients), GHRH (seven of seven patients), and TRH (seven of seven patients) and enhanced responses to GHRP plus GHRH (two of four patients) or TRH plus GHRH (six of six patients). In an in vitro dispersed cell study, the majority of patients examined also showed clear GH responses to GHRP (four of four patients), GHRH (six of six patients), and TRH (four of four patients) and an enhanced response to GHRP plus GHRH (three of three patients) or TRH plus GHRH (three of four patients). In one patient (no. 3), GHRP plus forskolin (adenylate cyclase activator), but not GHRP plus phorbol 12-myristate 13-acetate (protein kinase C activator), additively enhanced the GH response. Nordihydroguaiaretic acid (NDGA; inhibitor of arachidonic cascade) inhibited GH release induced by GHRP, TRH, GHRH, TRH plus GHRH, or GHRP plus GHRH, but did not inhibit basal GH secretion. In contrast, NDGA distinctly elevated intracellular cAMP levels in another patient (no. 7) when coadministered with GHRP, GHRH, or GHRP plus GHRH, whereas cAMP levels were not modified by single administration of GHRP and NDGA. The GH response to the combined administration of GHRP and GHRH was synergistic in this patient, but was additive in the other two patients. It is concluded that GHRP, TRH, and GHRH directly stimulate in vivo and in vitro GH release from human somatotropinomas, and GHRP and TRH mainly exert their action through activation of the phosphatidylinositol-protein kinase C pathway, whereas GHRH exerts its action through the adenylate cyclase-protein kinase A pathway. These three agents seem to release GH via the arachidonic cascade.
在7例肢端肥大症患者体内及体外研究了生长激素释放六肽(GHRP - 6)、生长激素释放激素(GHRH)和促甲状腺激素释放激素(TRH)的生长激素分泌机制。在一项体内研究中,这些患者对单次给予GHRP(4例患者中的4例)、GHRH(7例患者中的7例)和TRH(7例患者中的7例)均表现出明显的生长激素反应,对GHRP加GHRH(4例患者中的2例)或TRH加GHRH(6例患者中的6例)表现出增强反应。在一项体外分散细胞研究中,大多数接受检查的患者对GHRP(4例患者中的4例)、GHRH(6例患者中的6例)和TRH(4例患者中的4例)也表现出明显的生长激素反应,对GHRP加GHRH(3例患者中的3例)或TRH加GHRH(4例患者中的3例)表现出增强反应。在1例患者(3号)中,GHRP加福斯高林(腺苷酸环化酶激活剂)可增强生长激素反应,但GHRP加佛波酯12 - 肉豆蔻酸酯13 - 乙酸酯(蛋白激酶C激活剂)则不能。去甲二氢愈创木酸(NDGA;花生四烯酸级联反应抑制剂)可抑制GHRP、TRH、GHRH、TRH加GHRH或GHRP加GHRH诱导的生长激素释放,但不抑制基础生长激素分泌。相反,在另一例患者(7号)中,NDGA与GHRP、GHRH或GHRP加GHRH共同给药时可明显提高细胞内cAMP水平,而单独给予GHRP和NDGA时cAMP水平未改变。该患者对GHRP和GHRH联合给药的生长激素反应具有协同性,但在另外2例患者中为相加作用。结论是,GHRP、TRH和GHRH在体内和体外均可直接刺激人生长激素瘤释放生长激素,GHRP和TRH主要通过激活磷脂酰肌醇 - 蛋白激酶C途径发挥作用,而GHRH通过腺苷酸环化酶 - 蛋白激酶A途径发挥作用。这三种药物似乎通过花生四烯酸级联反应释放生长激素。